[go: up one dir, main page]

WO2009109991A3 - Novel hydrazide containing tyrosine kinase inhibitors - Google Patents

Novel hydrazide containing tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2009109991A3
WO2009109991A3 PCT/IN2009/000057 IN2009000057W WO2009109991A3 WO 2009109991 A3 WO2009109991 A3 WO 2009109991A3 IN 2009000057 W IN2009000057 W IN 2009000057W WO 2009109991 A3 WO2009109991 A3 WO 2009109991A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
containing tyrosine
hydrazide containing
novel hydrazide
Prior art date
Application number
PCT/IN2009/000057
Other languages
French (fr)
Other versions
WO2009109991A2 (en
Inventor
Prabal Sengupta
Chetan Surjitsingh Puri
Hemantkumar Chokshi
Trinadha Rao Chitturi
Rajamannar Thennati
Original Assignee
Sun Pharma Advanced Research Company Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd., filed Critical Sun Pharma Advanced Research Company Ltd.,
Publication of WO2009109991A2 publication Critical patent/WO2009109991A2/en
Publication of WO2009109991A3 publication Critical patent/WO2009109991A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I), and salts thereof, wherein P represents a 5 or 6-membered heteroaryl ring; R1 is aryl or unsaturated heterocyclyl radical optionally substituted by one or more identical or different radicals R5.
PCT/IN2009/000057 2008-01-23 2009-01-22 Novel hydrazide containing tyrosine kinase inhibitors WO2009109991A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN160MU2008 2008-01-23
IN160/MUM/2008 2008-01-23

Publications (2)

Publication Number Publication Date
WO2009109991A2 WO2009109991A2 (en) 2009-09-11
WO2009109991A3 true WO2009109991A3 (en) 2010-11-25

Family

ID=41056431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000057 WO2009109991A2 (en) 2008-01-23 2009-01-22 Novel hydrazide containing tyrosine kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2009109991A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
CA2812683C (en) 2009-09-25 2017-10-10 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
ES2607081T3 (en) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Lysine-1 specific demethylase inhibitors and their use
BR112013002164B1 (en) 2010-07-29 2021-11-09 Oryzon Genomics S.A. DEMETHYLASE INHIBITORS BASED ON LSD1 ARILCYCLOPROPYLAMINE, THEIR USES, AND PHARMACEUTICAL COMPOSITION
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20140163041A1 (en) * 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
RS58475B1 (en) 2011-10-20 2019-04-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CN104945388A (en) * 2015-07-09 2015-09-30 南京大学 Preparing method for 4-(3-(3-(4-clocoumarol)-acylhydrazone)-5-phenyl-pyrazol) benzene sulfonamide derivate and application to anti-cancer drugs
CN107056713A (en) * 2017-05-18 2017-08-18 厦门大学 4 ((pyrimidine radicals of 4 substituted aryl 2) amino) benzoyl hydrazine derivatives and its preparation method and application
CN113975271B (en) * 2021-09-02 2022-06-21 苏州大学附属第一医院 Application of small molecular compound in preparation of medicine for treating tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083654A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl amide derivatives as angiogenesis inhibitors
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083654A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl amide derivatives as angiogenesis inhibitors
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway

Also Published As

Publication number Publication date
WO2009109991A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
WO2007105058A8 (en) Pyrazole compounds
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
NO20060145L (en) Substituted indazolyl (indolyl) maleimide derivatives as kinase inhibitors
TW200633991A (en) Chemical compounds
EA201100189A1 (en) Heteroaryl Derivatives As DGAT1 Inhibitors
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
RS54199B1 (en) Process for preparing intermediates of compounds useful as opioid receptor modulators
WO2013053983A8 (en) Protein kinase inhibitors
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
TN2011000274A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
EA201000113A1 (en) PYRAZOL COMPOUNDS
NO20071073L (en) Heterocycle-substituted cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors
NO20071125L (en) Substituted indolyl-alkyl-amino derivatives as novel inhibitors of histone deacetylase
NO20085107L (en) Spirocyclic nitriles as protease inhibitors
RS53684B1 (en) PROSTACYCLINE (PGI2) MODULATORS FOR RECIPES USEFUL IN TREATMENT OF PGI2-related DISORDERS
EA201000101A1 (en) DERIVATIVES OF PYRIMIDINE 934
WO2008036967A3 (en) Novel heterocyclic compounds as lasy activators
MX2009011579A (en) Pyrimidinones as casein kinase ii (ck2) modulators.
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
MX394835B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA200801608A1 (en) DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID
EA201200891A1 (en) DERIVATIVES 3,4,4A, 10D-TETRAGIDRO-1H-TIOPIRANO [4,3-C] IZOHINOLINA
NO20081206L (en) Isoquinolines derivatives as IGF -1R inhibitors
NO20092341L (en) Substituted piperidines containing a heteroarylamide or a heteroarylphenyl group

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718021

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718021

Country of ref document: EP

Kind code of ref document: A2